Serial monitoring of NT-proBNP in T2DM patients may be useful to identify patients at highest risk of HF39, and guidelines recommend measurement of a natriuretic peptide in asymptomatic diabetic patients on at least a yearly basis to identify the earliest HF stages and implement strategies to prevent transition to symptomatic HF2. This evidence concerns the gene NPPB and type 2 diabetes mellitus.